Search

Your search keyword '"Freeman, Samuel S."' showing total 186 results

Search Constraints

Start Over You searched for: Author "Freeman, Samuel S." Remove constraint Author: "Freeman, Samuel S." Publication Year Range Last 10 years Remove constraint Publication Year Range: Last 10 years
186 results on '"Freeman, Samuel S."'

Search Results

1. Human lung cancer harbors spatially organized stem-immunity hubs associated with response to immunotherapy

2. Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer

4. Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort study

5. In vivo CRISPR screens reveal the landscape of immune evasion pathways across cancer

6. Landscape of helper and regulatory antitumour CD4+ T cells in melanoma

7. Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma

8. Genome-scale screens identify factors regulating tumor cell responses to natural killer cells

9. Transcriptomic Characterization of SF3B1 Mutation Reveals Its Pleiotropic Effects in Chronic Lymphocytic Leukemia

10. Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma

11. Structural Alterations Driving Castration-Resistant Prostate Cancer Revealed by Linked-Read Genome Sequencing

13. Genomic and immune profiling of pre-invasive lung adenocarcinoma

14. Spatial analysis of human lung cancer reveals organized immune hubs enriched for stem-like CD8 T cells and associated with immunotherapy response

15. Data from KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1

16. Supplementary Figures and Tables from KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1

17. Table S2 from The Lipogenic Regulator SREBP2 Induces Transferrin in Circulating Melanoma Cells and Suppresses Ferroptosis

18. Supplementary Methods from Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma

19. Supplementary Figure Legends from Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma

20. Data from Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma

21. Data from The Lipogenic Regulator SREBP2 Induces Transferrin in Circulating Melanoma Cells and Suppresses Ferroptosis

22. Supplementary Figures 1-4 from Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma

23. Supplementary Data from The Lipogenic Regulator SREBP2 Induces Transferrin in Circulating Melanoma Cells and Suppresses Ferroptosis

24. Supplementary Tables 1-8 from Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma

25. Supplementary Figure 4 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer

26. Supplementary Data from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer

27. Supplementary Figure 1 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer

28. Supplementary Figure 5 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer

29. Supplementary Figure 8 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer

30. Supplementary Figure 3 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer

31. Supplementary Figure 9 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer

32. Supplementary Figure 7 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer

33. Supplementary Figure 6 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer

34. Supplementary Tables from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer

35. Supplementary Figure 2 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer

37. Longitudinal characterization of circulating neutrophils uncovers phenotypes associated with severity in hospitalized COVID-19 patients

38. Structural Alterations Driving Castration-Resistant Prostate Cancer Revealed by Linked-Read Genome Sequencing

39. Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer

40. Abstract 3610: In vivo CRISPR screens reveal the landscape of immune evasion pathways across cancer

41. Abstract 2259: Predictive modeling of smoldering multiple myeloma progression to multiple myeloma by continuous variable analysis

42. GeneVector: Identification of transcriptional programs using dense vector representations defined by mutual information

43. Integrative Analysis of Checkpoint Blockade Response in Advanced Non-Small Cell Lung Cancer

44. Combined tumor and immune signals from genomes or transcriptomes predict outcomes of checkpoint inhibition in melanoma

45. Implementation of a prostate cancer‐specific targeted sequencing panel for credentialing of patient‐derived cell lines and genomic characterization of patient samples

46. Genomic aberrations in cervical adenocarcinomas in Hong Kong Chinese women

47. Longitudinal characterization of circulating neutrophils uncovers distinct phenotypes associated with disease severity in hospitalized COVID-19 patients

48. Combined tumor and immune signals from genomes or transcriptomes predict outcomes of checkpoint inhibition in melanoma

49. Genome-scale screens identify factors regulating tumor cell responses to natural killer cells

50. The Lipogenic Regulator SREBP2 Induces Transferrin in Circulating Melanoma Cells and Suppresses Ferroptosis

Catalog

Books, media, physical & digital resources